Full access
Clinical & Research News
Published Online: 4 March 2011

Different Approaches Used to Create Cocaine Vaccine

Publication: Psychiatric News
Volume 46, Number 5
https://doi.org/10.1176/pn.46.5.psychnews_46_5_20_3
Track CitationsAdd to favorites
Ron Crystal, M.D., and colleagues used a disrupted cold virus to which they attached cocaine molecules to create a vaccine that would inhibit cocaine from entering the brains of mice and were largely successful (see Cocaine Vaccination Isn't Science Fiction Anymore).
"We took advantage of the fact that the body has such a robust immune response to the cold virus," Crystal told Psychiatric News.
Others have tested a cocaine vaccine in humans, but used slightly different techniques.
For instance, Thomas Kosten, M.D., and colleagues at Baylor College of Medicine in Houston and Yale University School of Medicine from 2003 to 2005 conducted a clinical trial in which they chemically bonded cocaine molecules to a protein derived from a cholera toxin to form a vaccine, which they used in human subjects.
Specifically, they randomly assigned 58 subjects to receive the cocaine vaccine in five intramuscular injections spaced over 12 weeks, while 57 subjects received a placebo injection on an identical schedule.
On average, all of the study subjects had abused cocaine for 15 years.
Kosten found that vaccinated patients demonstrated varying levels of antibody responses, and only 38 percent of the 55 who completed the entire series of injections produced anti-cocaine antibodies in the quantity (at least 43 mg/mL of blood) that researchers estimated would reliably block drug-induced euphoria.
During the eight weeks of the greatest antibody response, this group provided cocaine-free urine samples 45 percent of the time, as compared with 35 percent for the placebo group and the group with a lesser response to the vaccine.
Of the patients who produced euphoria-blocking antibody levels, 53 percent at least doubled the frequency with which their urine samples showed no cocaine use. Of those who didn't produce high levels of anti-cocaine antibodies, only 23 percent doubled the frequency with which they produced cocaine-free urine samples.
Crystal acknowledged that this research is encouraging, but commented that by bonding cocaine molecules to the cold virus, he hopes to produce a stronger and more consistent immune response in human subjects.

Information & Authors

Information

Published In

Go to Psychiatric News
Psychiatric News
Volume 46 • Number 5 • March 4, 2011
Pages: 20

History

Published online: 4 March 2011
Published in print: March 4, 2011

Authors

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard
Tips for downloading citations

View Options

View options

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share

×

As described within the American Psychiatric Association (APA)'s Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences. Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.